Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Specimen Handling 271 Magnetic Resonance Spectroscopy 222 pembrolizumab 216 Carboplatin 175 Biopsy 166 Cisplatin 155 Nivolumab 150 Cyclophosphamide 135 Paclitaxel 120 Radiotherapy 117 Gemcitabine 111 Bevacizumab 93 durvalumab 85 Dexamethasone 83 Rituximab 76 Oxaliplatin 71 atezolizumab 70 Doxorubicin 67 Capecitabine 67 Fluorouracil 66 venetoclax 65 Etoposide 64 Docetaxel 64 Radiosurgery 58 Radiation 57 Cytarabine 57 Prednisone 56 Pemetrexed 55 Ipilimumab 55 Lenalidomide 54

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × DLL3 protein, human × 90 days × Clear all

NCT06893783 2026-04-13

DeLLight

Asan Medical Center

Phase 2 Recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡